Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309657069> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4309657069 endingPage "41" @default.
- W4309657069 startingPage "41" @default.
- W4309657069 abstract "Diabetes has a negative impact on patient's quality of life (QoL). Comorbidities and polypharmacy further worsen their QoL. Thus, in addition to glycemic control, assessment of QoL is also gaining importance.The objective of this study was to evaluate QoL in patients of type 2 diabetes mellitus (T2DM) with hypertension after add-on empagliflozin to triple drug therapy (metformin, teneligliptin, and glimepiride).A prospective research was done on T2DM patients with hypertension, who visited a tertiary care referral institute's endocrine outpatient clinic. For 3 months, empagliflozin, 25 mg once daily, was administered as an add-on treatment with metformin, teneligliptin, and glimepiride. In addition to clinical assessment, an Urdu-translated QoL instrument for Indian diabetes patients was used to conduct QoL study. The QoL outcomes prior to empagliflozin add-on were compared with those obtained at the conclusion of the 3 months of treatment.Empagliflozin as an add-on therapy significantly improved various aspects of QoL like role limitation due to physical health, physical endurance, general health, symptom botherness, financial worries, emotional/mental health, and diet satisfaction (P < 0.001). It also improved glycemic and blood pressure parameters significantly.QoL is an essential measure with respect to patient-centered treatment approach. Empagliflozin, as an add-on medication, improved QoL, glycemic parameters and blood pressure in T2DM patients with hypertension. It can be recommended as an add-on, but more research with a larger sample size is required." @default.
- W4309657069 created "2022-11-29" @default.
- W4309657069 creator A5004905869 @default.
- W4309657069 creator A5012390478 @default.
- W4309657069 creator A5055985981 @default.
- W4309657069 creator A5072418383 @default.
- W4309657069 creator A5087963519 @default.
- W4309657069 creator A5066862936 @default.
- W4309657069 date "2022-01-01" @default.
- W4309657069 modified "2023-09-25" @default.
- W4309657069 title "Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study" @default.
- W4309657069 doi "https://doi.org/10.4103/ijph.ijph_1070_22" @default.
- W4309657069 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36412472" @default.
- W4309657069 hasPublicationYear "2022" @default.
- W4309657069 type Work @default.
- W4309657069 citedByCount "0" @default.
- W4309657069 crossrefType "journal-article" @default.
- W4309657069 hasAuthorship W4309657069A5004905869 @default.
- W4309657069 hasAuthorship W4309657069A5012390478 @default.
- W4309657069 hasAuthorship W4309657069A5055985981 @default.
- W4309657069 hasAuthorship W4309657069A5066862936 @default.
- W4309657069 hasAuthorship W4309657069A5072418383 @default.
- W4309657069 hasAuthorship W4309657069A5087963519 @default.
- W4309657069 hasBestOaLocation W43096570691 @default.
- W4309657069 hasConcept C126322002 @default.
- W4309657069 hasConcept C134018914 @default.
- W4309657069 hasConcept C159110408 @default.
- W4309657069 hasConcept C1862650 @default.
- W4309657069 hasConcept C2775887513 @default.
- W4309657069 hasConcept C2776307423 @default.
- W4309657069 hasConcept C2777180221 @default.
- W4309657069 hasConcept C2779951463 @default.
- W4309657069 hasConcept C2780323712 @default.
- W4309657069 hasConcept C2780473172 @default.
- W4309657069 hasConcept C2910068830 @default.
- W4309657069 hasConcept C555293320 @default.
- W4309657069 hasConcept C71924100 @default.
- W4309657069 hasConcept C84393581 @default.
- W4309657069 hasConceptScore W4309657069C126322002 @default.
- W4309657069 hasConceptScore W4309657069C134018914 @default.
- W4309657069 hasConceptScore W4309657069C159110408 @default.
- W4309657069 hasConceptScore W4309657069C1862650 @default.
- W4309657069 hasConceptScore W4309657069C2775887513 @default.
- W4309657069 hasConceptScore W4309657069C2776307423 @default.
- W4309657069 hasConceptScore W4309657069C2777180221 @default.
- W4309657069 hasConceptScore W4309657069C2779951463 @default.
- W4309657069 hasConceptScore W4309657069C2780323712 @default.
- W4309657069 hasConceptScore W4309657069C2780473172 @default.
- W4309657069 hasConceptScore W4309657069C2910068830 @default.
- W4309657069 hasConceptScore W4309657069C555293320 @default.
- W4309657069 hasConceptScore W4309657069C71924100 @default.
- W4309657069 hasConceptScore W4309657069C84393581 @default.
- W4309657069 hasIssue "5" @default.
- W4309657069 hasLocation W43096570691 @default.
- W4309657069 hasLocation W43096570692 @default.
- W4309657069 hasLocation W43096570693 @default.
- W4309657069 hasOpenAccess W4309657069 @default.
- W4309657069 hasPrimaryLocation W43096570691 @default.
- W4309657069 hasRelatedWork W1986052847 @default.
- W4309657069 hasRelatedWork W1996036642 @default.
- W4309657069 hasRelatedWork W2038801186 @default.
- W4309657069 hasRelatedWork W2052503411 @default.
- W4309657069 hasRelatedWork W2927285401 @default.
- W4309657069 hasRelatedWork W3116386123 @default.
- W4309657069 hasRelatedWork W3157159447 @default.
- W4309657069 hasRelatedWork W4220745692 @default.
- W4309657069 hasRelatedWork W4322757122 @default.
- W4309657069 hasRelatedWork W1560540538 @default.
- W4309657069 hasVolume "66" @default.
- W4309657069 isParatext "false" @default.
- W4309657069 isRetracted "false" @default.
- W4309657069 workType "article" @default.